Ozempic vs Wegovy vs Mounjaro vs Trulicity (2026): Evidence-Based Comparison of GLP-1 Weight Loss Drugs
Updated October 2026 · This article focuses on the weekly injectable products. U.S. FDA indications are used for the regulatory comparison; availability, brand names, dosing and approvals can differ in Malaysia and other countries. Ozempic, Wegovy, Mounjaro and Trulicity are not simply four versions of the same drug. Ozempic and Wegovy contain semaglutide; Mounjaro contains tirzepatide; and Trulicity contains dulaglutide. The most important pharmacologic difference is that tirzepatide activates both GIP and GLP-1 receptors , whereas the other three are GLP-1 receptor agonists. For weight loss, the 2026 picture is more nuanced than it was a few years ago. Tirzepatide has produced greater average weight loss than semaglutide in a direct head-to-head obesity trial. At the same time, semaglutide has moved into a new phase with Wegovy HD 7.2 mg , approved by the U.S. FDA in March 2026 for additional weight reduction in appropriate adults. Bottom line: For obesity treatment,...